- Home
- SEV vs COCH Comparison
SEV vs COCH Comparison
Compare SEV & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEV | COCH |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.2M | 51.3M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEV | COCH |
|---|---|---|
| Price | $2.08 | $7.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.33 | ★ $21.67 |
| AVG Volume (30 Days) | ★ 252.3K | 18.5K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25,146.67 | $17.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $1.29 | $4.72 |
| 52 Week High | $8.80 | $47.70 |
Technical Indicators
Market Signals| Indicator | SEV | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 14.75 |
| Support Level | $1.76 | $4.72 |
| Resistance Level | $1.98 | $36.51 |
| Average True Range (ATR) | 0.12 | 0.64 |
| MACD | 0.06 | 0.35 |
| Stochastic Oscillator | 78.13 | 80.17 |
Price Performance
Historical ComparisonAbout SEV Aptera Motors Corp.
Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.